Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781

Activated T cells drive a range of immune-mediated inflammatory diseases. LAG-3 is transiently expressed on recently activated CD4(+) and CD8(+) T cells. We describe the engineering and first-in-human clinical study (NCT02195349) of GSK2831781 (an afucosylated humanized IgG1 monoclonal antibody enhanced with high affinity for Fc receptors and LAG-3 and antibody-dependent cellular cytotoxicity capabilities), which depletes LAG-3 expressing cells. GSK2831781 was tested in a phase I/Ib, double-blind, placebo-controlled clinical study, which randomized 40 healthy participants (part A) and 27 patients with psoriasis (part B) to single doses of GSK2831781 (up to 0.15 and 5 mg/kg, respectively) or placebo. Adverse events were generally balanced across groups, with no safety or tolerability concern identified. LAG-3(+) cell depletion in peripheral blood was observed at doses >= 0.15 mg/kg and was dose-dependent. In biopsies of psoriasis plaques, a reduction in mean group LAG-3(+) and CD3(+) T-cell counts was observed following treatment. Downregulation of proinflammatory genes (IL-17A, IL-17F, IFN gamma, and S100A12) and upregulation of the epithelial barrier integrity gene, CDHR1, was observed with the 5 mg/kg dose of GSK2831781. Psoriasis disease activity improved up to day 43 at all GSK2831781 doses (0.5, 1.5, and 5 mg/kg) compared with placebo. Depletion of LAG-3-expressing activated T cells is a novel approach, and this first clinical study shows that GSK2831781 is pharmacologically active and provides encouraging early evidence of clinical effects in psoriasis, which warrants further investigation in T-cell-mediated inflammatory diseases.

Automated summary

GSK2831781, a novel afucosylated humanized IgG1 monoclonal antibody that depletes LAG-3 expressing cells, showed promising pharmacological activity in a phase I/Ib clinical study for psoriasis. The treatment led to significant reduction in LAG-3(+) and CD3(+) T-cell counts in psoriasis plaques, along with modulation of proinflammatory and epithelial barrier integrity genes. Psoriasis disease activity improved with GSK2831781, supporting further investigation in T-cell-mediated inflammatory diseases.